Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles with leads to massive expansion of antigen-specific Tregs
Time: 2:00 pm
day: Day One
Details:
- Engineered IL-2 molecules selective for the high affinity IL-2 receptor expressedon Tregs have been shown to non-selectively expand Tregs in vivo and are being developed for the treatment of autoimmune diseases
- We have developed tolerogenic nanoparticles that have been shown to induce antigen-specific immune tolerance and are in Phase 3 clinical trials in
combination with a highly immunogenic fungal-derived uricase enzyme for the treatment of uncontrolled gout - Here we demonstrate that ImmTOR combined with a Treg-selective IL-2 molecule shows profound synergistic activity in animal studies resulting in massive expansion of antigen-specific Tregs
